Author Affiliations: Division of Cardiology, Emory University, Atlanta, Georgia (Dr Quyyumi); and John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey (Dr Pecora) (email@example.com).
To the Editor: Dr Traverse and colleagues observed no differences at 6 months in global or regional LV function, infarct size, or infarct volumes in patients with LV dysfunction as a consequence of an MI who received intracoronary infusion of autologous BMCs compared with controls.1 The authors attributed the lack of efficacy when compared with similar trials that found an improvement in LV function in part to the late time of infusion (median: 17.4 days vs 7 days in prior studies) when BMC homing signals from ischemic cardiomyocytes have diminished. We believe the authors did not address a more likely cause for lack of efficacy in their trial: infusion of an insufficient number of potent cells.
Quyyumi A, Pecora AL. Intracoronary Bone Marrow Mononuclear Cells After Myocardial Infarction. JAMA. 2012;307(10):1022-1024. doi:10.1001/jama.2012.279